Report of the UK Cystic Fibrosis Trust Antibiotic Working Group

107. Deerojanawong J, Sawyer SM, Fink AM, Stokes KB, Robertson CF. Totally implantable venous access devices inchildren with cystic fibrosis: incidence and type of complications. Thorax 1998;53:285–9.108. Burdon J, Conway SP, Murchan P, Lansdown M, Kester RC. Five years’ experience of PAS Port intravenous accesssystem in adult cystic fibrosis. Eur Respir J 1998;12:212–6.109. Ratnalingham RA, Peckham D, Denton M, Kerr K, Conway S. Stenotrophomonas maltophilia bacteraemia in twopatients with cystic fibrosis associated with totally implantable venous access devices. J Infect 2002;44:53–5.110. Kariyawasam HH, Pepper JR, Hodson ME, Geddes DM. Experience of totally implantable venous access devices(TIV ADs) in adults with cystic fibrosis over a 13-year period. Respir Med 2000;94:1161–5.111. Fahy JV, Keoghan MT, Crummy EJ, FitzGerald MX. Bacteraemia and fungaemia in adults with cystic fibrosis. JInfect 1991;22:241–5.112. Horn CK,.Conway SP. Candidaemia: risk factors in patients with cystic fibrosis who have totally implantablevenous access systems. J Infect 1993;26:127–32.113. Bonacorsi SP, Munck A, Gerardin M, Doit C, Brahimi N, Navarro J et al. In situ management and molecularanalysis of candidaemia related to a totally implantable vascular access in a cystic fibrosis patient. J Infect1996;33:49–51.114. Horn CK,.Conway SP. Candidaemia: risk factors in patients with cystic fibrosis who have totally implantablevenous access systems. J Infect 1993;26:127–32.115. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE et al. Practice guidelines for the treatment ofcandidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662–78.116. Oermann CM, Starke JR, Seilheimer DK. Pulmonary disease caused by Mycobacterium kansasii in a patient withcystic fibrosis. Pediatr Infect Dis J 1997;16:257–9.117. Torrens JK, Dawkins P, Conway SP, Moya E. Non-tuberculous mycobacteria in cystic fibrosis. Thorax1998;53:182–5.118. Hjelte L, Petrini B, Kallenius G, Strandvik B. Prospective study of mycobacterial infections in patients with cysticfibrosis. Thorax 1990;45:397–400.119. Kilby JM, Gilligan PH, Yankaskas JR, Highsmith WE, Jr., Edwards LJ, Knowles MR. Nontuberculousmycobacteria in adult patients with cystic fibrosis. Chest 1992;102:70–5.120. Aitken ML, Burke W, McDonald G, Wallis C, Ramsey B, Nolan C. Nontuberculous mycobacterial disease in adultcystic fibrosis patients. Chest 1993;103:1096–9.121. Fauroux B, Delaisi B, Clement A, Saizou C, Moissenet D, Truffot-Pernot C et al. Mycobacterial lung disease incystic fibrosis: a prospective study. Pediatr Infect Dis J 1997;16:354–8.122. Whittier S, Olivier K, Gilligan P, Knowles M, Della-Latta P. Proficiency testing of clinical microbiologylaboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputumsamples from cystic fibrosis patients. The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. J ClinMicrobiol 1997;35:2706–8.123. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL et al. Nontuberculous mycobacteria. II: nestedcohortstudy of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:835–40.124. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F et al. An official ATS/IDSA statement:diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med2007;175:367–416.125. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL et al. Nontuberculous mycobacteria. II: nestedcohortstudy of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:835–40.126. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL et al. Nontuberculous mycobacteria. II: nestedcohortstudy of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:835–40.127. Cullen AR, Cannon CL, Mark EJ, Colin AA. Mycobacterium abscessus infection in cystic fibrosis. Colonization orinfection? Am J Respir Crit Care Med 2000;161:641–5.128. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL et al. Nontuberculous mycobacteria. II: nestedcohortstudy of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:835–40.129. Fauroux B, Delaisi B, Clement A, Saizou C, Moissenet D, Truffot-Pernot C et al. Mycobacterial lung disease incystic fibrosis: a prospective study. Pediatr Infect Dis J 1997;16:354–8.130. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL et al. Nontuberculous mycobacteria. II: nestedcohortstudy of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:835–40.131. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL et al. Nontuberculous mycobacteria. II: nestedcohortstudy of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:835–40.Cystic Fibrosis Trust 7.10March 2009